Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 548 across all filing types
Latest filing 2023-02-23 AGM Information
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis annonce la convocation d’une assemblée générale mixte le 30 mars 2023
AGM Information Classification · 98% confidence The document is titled "Communiqué de presse" (Press Release) and its main subject is the announcement of an upcoming 'assemblée générale mixte' (combined extraordinary and ordinary general meeting) scheduled for March 30, 2023. The text details key resolutions to be voted upon, such as delegation to the Board for nominal value reduction and share consolidation. This type of announcement, which calls for a shareholder meeting and outlines the agenda, strongly aligns with the purpose of an Annual General Meeting (AGM) announcement or related preparatory materials. Since the document explicitly calls for a general meeting and discusses resolutions to be voted on, the most appropriate classification is AGM-R (AGM Information), which covers presentations and materials shared during the AGM, or potentially PSI (Proxy Solicitation & Information Statement) if it were the full proxy document, but the press release format points more directly to the event itself being announced. Given the focus on convening the meeting and the resolutions, AGM-R is the best fit among the provided options, as it relates directly to the general meeting event.
2023-02-23 French
Biophytis annonce les résultats finaux positifs de son étude COVA de phase 2-3 avec Sarconeos (BIO101) dans les formes sévères de COVID-19
Earnings Release Classification · 99% confidence The document is a press release dated February 2, 2023, announcing the final positive results of the COVA Phase 2-3 study for Sarconeos (BIO101) in severe COVID-19 patients. It details the primary endpoint achievement (44% reduction in respiratory failure or early death risk) and outlines the next steps, including filing for early access programs and market authorization applications (conditional marketing authorization in Europe and EUA in the US). This content—announcing key financial/clinical results and immediate strategic next steps—is characteristic of an Earnings Release (ER) or a general press release detailing significant operational news. Since it focuses on the *results* and the immediate regulatory/access strategy following those results, it aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical financial/operational results (clinical trial results being a key operational result for a biotech). It is not a full Annual Report (10-K), a transcript (CT), or a dedicated management discussion (MDA), but rather the initial public announcement of the outcome. FY 2023
2023-02-02 French
Biophytis publie ses résultats financiers du 1er semestre 2022
Earnings Release Classification · 95% confidence The document is a press release from Biophytis announcing their H1 2022 financial results and corrected 2021 financial statements. While it contains financial tables, it is structured as a corporate communication (press release) rather than a formal, comprehensive interim report. According to the 'Menu vs Meal' rule, this is an announcement of results rather than the full report itself. Therefore, it is classified as an Earnings Release (ER). H1 2022
2023-01-31 French
Arrêt de la Cour d'appel de Paris du 17 janvier 2023 dans l'affaire opposant Biophytis à Negma Group Ltd
Legal Proceedings Report Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces the outcome of an appeal judgment regarding a legal dispute between Biophytis and Negma Group Ltd. It details the court's decision, including financial penalties. This type of announcement, concerning significant legal proceedings or regulatory actions, fits best under the Legal Proceedings Report category. Although it is a press release, the core content is the update on a lawsuit, not just the announcement of a report's publication (RPA) or a general regulatory filing (RNS). The length (4890 chars) is substantial enough to contain the substance of the update, rather than just being a placeholder for a larger document.
2023-01-19 French
Biophytis prévoit de prendre les mesures appropriées après avoir reçu l’avis de carence du Nasdaq
Regulatory Filings Classification · 95% confidence The document is a press release dated January 12, 2023, announcing that Biophytis received a deficiency notice from Nasdaq because it failed to file its financial information for the six months ended June 30, 2022, on a Form 6-K. This document is an announcement regarding a regulatory compliance issue (failure to file a required periodic report) and the subsequent steps to regain compliance. It is not the actual financial report (like an IR or 10-K) nor is it a general earnings release (ER). Since it discusses a specific regulatory filing failure (Form 6-K, which is typically filed by foreign private issuers for material events or periodic reports not covered by 20-F), and it is a formal announcement about a compliance matter, it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory event announcement, or potentially LTR if the non-compliance itself is viewed as a legal/regulatory matter. However, RNS is the best fit for general regulatory announcements that aren't explicitly covered by other codes like DIV, DIRS, or MANG. Given the context of non-compliance with listing rules due to missing periodic filings, RNS serves as the most appropriate general regulatory announcement category.
2023-01-12 French
Biophytis prévoit de prendre les mesures appropriées après avoir reçu l’avis de carence du Nasdaq
Delisting Announcement Classification · 99% confidence The document is a press release from Biophytis announcing that it received a deficiency notice from Nasdaq because it failed to file its financial information for the six months ended June 30, 2022, on a Form 6-K. This document is an announcement regarding a regulatory compliance issue and the company's plan to address it. It is not the actual financial report (like an IR or 10-K) nor is it a general earnings release (ER). Since it discusses regulatory compliance failure and the need to file specific SEC forms (6-K mentioned), it falls under general regulatory communication. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific regulatory compliance announcement that doesn't fit other categories, although it is closely related to SEC filing requirements. However, the core content is an announcement about a compliance failure related to periodic reporting, which often accompanies or precedes other filings. Since it is a press release announcing a regulatory status issue, RNS is the best fit as a general regulatory announcement.
2023-01-12 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.